

# Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

NCT07037433

---

Status	RECRUITING
Phase	Phase 3
Sponsor	Amgen
Enrollment	12,800 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Age e 45 years at screening.
  - BMI of e 27.0 kg/m<sup>2</sup> at screening.
  - History of Atherosclerotic Cardiovascular Disease (ASCVD) with a documented history of at least one of the following:
  - Prior MI (presumed atherothrombotic event due to plaque rupture/erosion).
  - Prior ischemic stroke (presumed due to atherosclerosis; may include ischemic stroke with hemorrhagic transformation).
- ... and 1 more (see full listing online)

### Exclusion (15)

- History of any of the following within 60 days before screening or between screening and randomization: MI, hospitalization for unstable angina, arterial revascularization (eg, coronary, cerebrovascular or peripheral) major cardiovascular surgery, stroke, or transient ischemic attack (TIA).
  - New York Heart Association (NYHA) class IV HF during screening or hospitalization for HF within 60 days before screening or between screening and randomization.
  - Type 1 DM, or any other type of diabetes with the exception of T2DM or prior gestational diabetes. Participants with a history of gestational diabetes should be stratified according to their current diabetes classification.
  - For participants with T2DM (including those without a prior history of T2DM but with a HbA1c e 6.5% during screening):
  - HbA1c \> 10.0% (86 mmol/mol) at screening.
- ... and 10 more (see full listing online)

## Locations (726 total)

---

Alliance For Multispecialty Research - Daphne, Daphne, Alabama, United States  
Eastern Shore Research Institute, Fairhope, Alabama, United States  
Heart Center Research LLC, Huntsville, Alabama, United States  
... and 723 more locations

---

<https://clinicaltrials.gov/study/NCT07037433>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.